116 related articles for article (PubMed ID: 25341995)
1. Anti-tumor immunological response induced by cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell prostate cancer murine model.
Li F; Guo Z; Yu H; Zhang X; Si T; Liu C; Yang X; Qi L
Neoplasma; 2014; 61(6):659-71. PubMed ID: 25341995
[TBL] [Abstract][Full Text] [Related]
2. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.
Waitz R; Solomon SB; Petre EN; Trumble AE; Fassò M; Norton L; Allison JP
Cancer Res; 2012 Jan; 72(2):430-9. PubMed ID: 22108823
[TBL] [Abstract][Full Text] [Related]
3. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.
Benzon B; Glavaris SA; Simons BW; Hughes RM; Ghabili K; Mullane P; Miller R; Nugent K; Shinder B; Tosoian J; Fuchs EJ; Tran PT; Hurley PJ; Vuica-Ross M; Schaeffer EM; Drake CG; Ross AE
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):126-136. PubMed ID: 29556048
[TBL] [Abstract][Full Text] [Related]
4. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
[TBL] [Abstract][Full Text] [Related]
5. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
6. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
7. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
[TBL] [Abstract][Full Text] [Related]
8. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
9. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
10. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
11. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
13. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.
Olson BM; Jankowska-Gan E; Becker JT; Vignali DA; Burlingham WJ; McNeel DG
J Immunol; 2012 Dec; 189(12):5590-601. PubMed ID: 23152566
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells.
Motoshima T; Komohara Y; Horlad H; Takeuchi A; Maeda Y; Tanoue K; Kawano Y; Harada M; Takeya M; Eto M
Oncol Rep; 2015 Jun; 33(6):2947-53. PubMed ID: 25845968
[TBL] [Abstract][Full Text] [Related]
15. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
16. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model.
Liu Q; Ma P; Liu L; Ma G; Ma J; Liu X; Liu Y; Lin W; Zhu Y
Eur J Pharm Sci; 2017 Jan; 96():542-550. PubMed ID: 27989857
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent effect of anti-CTLA-4 on survival in sepsis.
Inoue S; Bo L; Bian J; Unsinger J; Chang K; Hotchkiss RS
Shock; 2011 Jul; 36(1):38-44. PubMed ID: 21368717
[TBL] [Abstract][Full Text] [Related]
19. Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer.
Youlin K; Li Z; Xiaodong W; Xiuheng L; Hengchen Z
Clin Dev Immunol; 2012; 2012():439235. PubMed ID: 22312406
[TBL] [Abstract][Full Text] [Related]
20. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Selby MJ; Engelhardt JJ; Quigley M; Henning KA; Chen T; Srinivasan M; Korman AJ
Cancer Immunol Res; 2013 Jul; 1(1):32-42. PubMed ID: 24777248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]